Charlotte Kervran, Florence Francis-Oliviero, Marion Kret, Adrianna Burtin, Rebecca Ratel, Estelle Clet, Fidéline Collin, Séverine Martiren, Claire Brandet, Judith Martin-Fernandez, Sarah Perrin, Carla Monin, Linda Cambon, Marc Auriacombe, Loïc Sentilhes, François Alla
{"title":"针对在产房刚分娩并在孕期吸烟的妇女和成瘾护理专业人员的组织干预措施的效果评估(5A-QUIT-N):阶梯式分组随机试验的研究方案。","authors":"Charlotte Kervran, Florence Francis-Oliviero, Marion Kret, Adrianna Burtin, Rebecca Ratel, Estelle Clet, Fidéline Collin, Séverine Martiren, Claire Brandet, Judith Martin-Fernandez, Sarah Perrin, Carla Monin, Linda Cambon, Marc Auriacombe, Loïc Sentilhes, François Alla","doi":"10.1136/bmjopen-2024-087541","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In 2021, among French women who smoked when they knew they were pregnant, 59% still smoked at the end of pregnancy. Support for pregnant women to stop smoking must include a structured organisational perspective. The main objective of the study is to evaluate the effectiveness of the 5A-QUIT-N organisational intervention on smoking cessation at delivery among pregnant women who smoke during pregnancy.</p><p><strong>Methods and analysis: </strong>The overarching goal of the 5A-QUIT-N intervention, which aims to organise the healthcare professionals monitoring pregnancy, specialists in addiction and tobacco use, and clinical and training tools, using the 5As method. The 5A-QUIT-N intervention will be evaluated in a pragmatic stepped-wedge cluster randomised trial. Within each cluster, during the 6 months before (control) and after (intervention) the intervention, women who smoke tobacco during pregnancy will be enrolled during their maternity stay after delivery. A transition period is planned between the control and intervention periods to deploy the intervention. All participating women will be interviewed using a heteroquestionnaire to assess smoking cessation, tobacco use monitoring by healthcare professionals and individual factors associated with tobacco use during pregnancy. The primary outcome was the point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. 4200 women who smoked tobacco during pregnancy will be recruited over the entire study period (33 months) to evaluate the effectiveness. An estimated 4585 participants will be included for all aims.</p><p><strong>Ethics and dissemination: </strong>The study will be implemented in accordance with French regulations. The study including the consent process has been independently reviewed and approved by the French ethical board 'CPP Ile de France I' on 10 February 2022 (No CPPIDF1-2022-DI08-cat.2). The results will be disseminated on various academic and non-academic platforms. The results will be reported in international peer-reviewed journals and presented at international and national conferences.</p>","PeriodicalId":9158,"journal":{"name":"BMJ Open","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness evaluation of an organisational intervention, targeting pregnancy and addiction care professionals, among women who have just given birth in maternity wards and smoked tobacco during pregnancy (5A-QUIT-N): study protocol for a stepped-wedge cluster randomised trial.\",\"authors\":\"Charlotte Kervran, Florence Francis-Oliviero, Marion Kret, Adrianna Burtin, Rebecca Ratel, Estelle Clet, Fidéline Collin, Séverine Martiren, Claire Brandet, Judith Martin-Fernandez, Sarah Perrin, Carla Monin, Linda Cambon, Marc Auriacombe, Loïc Sentilhes, François Alla\",\"doi\":\"10.1136/bmjopen-2024-087541\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>In 2021, among French women who smoked when they knew they were pregnant, 59% still smoked at the end of pregnancy. Support for pregnant women to stop smoking must include a structured organisational perspective. The main objective of the study is to evaluate the effectiveness of the 5A-QUIT-N organisational intervention on smoking cessation at delivery among pregnant women who smoke during pregnancy.</p><p><strong>Methods and analysis: </strong>The overarching goal of the 5A-QUIT-N intervention, which aims to organise the healthcare professionals monitoring pregnancy, specialists in addiction and tobacco use, and clinical and training tools, using the 5As method. The 5A-QUIT-N intervention will be evaluated in a pragmatic stepped-wedge cluster randomised trial. Within each cluster, during the 6 months before (control) and after (intervention) the intervention, women who smoke tobacco during pregnancy will be enrolled during their maternity stay after delivery. A transition period is planned between the control and intervention periods to deploy the intervention. All participating women will be interviewed using a heteroquestionnaire to assess smoking cessation, tobacco use monitoring by healthcare professionals and individual factors associated with tobacco use during pregnancy. The primary outcome was the point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. 4200 women who smoked tobacco during pregnancy will be recruited over the entire study period (33 months) to evaluate the effectiveness. An estimated 4585 participants will be included for all aims.</p><p><strong>Ethics and dissemination: </strong>The study will be implemented in accordance with French regulations. The study including the consent process has been independently reviewed and approved by the French ethical board 'CPP Ile de France I' on 10 February 2022 (No CPPIDF1-2022-DI08-cat.2). The results will be disseminated on various academic and non-academic platforms. The results will be reported in international peer-reviewed journals and presented at international and national conferences.</p>\",\"PeriodicalId\":9158,\"journal\":{\"name\":\"BMJ Open\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-11-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Open\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjopen-2024-087541\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/bmjopen-2024-087541","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
简介2021 年,在知道自己怀孕时吸烟的法国妇女中,59% 的人在妊娠结束时仍然吸烟。为孕妇提供戒烟支持必须包括结构化的组织视角。本研究的主要目的是评估5A-QUIT-N组织干预对孕期吸烟孕妇分娩时戒烟的效果:5A-QUIT-N干预措施的总体目标是利用5A方法组织监测妊娠期的医护人员、成瘾和烟草使用方面的专家以及临床和培训工具。5A-QUIT-N干预措施将在一项务实的阶梯式分组随机试验中进行评估。在每个群组中,在干预前(对照组)和干预后(干预组)的 6 个月内,怀孕期间吸烟的妇女将在分娩后的产褥期内进行登记。计划在对照期和干预期之间设立一个过渡期,以部署干预措施。所有参与研究的妇女都将接受异质性问卷调查,以评估戒烟情况、医护人员对烟草使用的监测情况以及与孕期烟草使用相关的个体因素。主要结果是分娩时戒烟的点流行率,即报告分娩时戒烟至少 7 天的妇女比例。在整个研究期间(33 个月),将招募 4200 名孕期吸烟的妇女,以评估其有效性。伦理和传播:这项研究将按照法国的相关规定进行。该研究(包括同意程序)已于 2022 年 2 月 10 日通过法国伦理委员会 "CPP Ile de France I "的独立审查和批准(编号 CPPIDF1-2022-DI08-cat.2)。研究成果将在各种学术和非学术平台上传播。成果将在国际同行评审期刊上发表,并在国际和国内会议上介绍。
Effectiveness evaluation of an organisational intervention, targeting pregnancy and addiction care professionals, among women who have just given birth in maternity wards and smoked tobacco during pregnancy (5A-QUIT-N): study protocol for a stepped-wedge cluster randomised trial.
Introduction: In 2021, among French women who smoked when they knew they were pregnant, 59% still smoked at the end of pregnancy. Support for pregnant women to stop smoking must include a structured organisational perspective. The main objective of the study is to evaluate the effectiveness of the 5A-QUIT-N organisational intervention on smoking cessation at delivery among pregnant women who smoke during pregnancy.
Methods and analysis: The overarching goal of the 5A-QUIT-N intervention, which aims to organise the healthcare professionals monitoring pregnancy, specialists in addiction and tobacco use, and clinical and training tools, using the 5As method. The 5A-QUIT-N intervention will be evaluated in a pragmatic stepped-wedge cluster randomised trial. Within each cluster, during the 6 months before (control) and after (intervention) the intervention, women who smoke tobacco during pregnancy will be enrolled during their maternity stay after delivery. A transition period is planned between the control and intervention periods to deploy the intervention. All participating women will be interviewed using a heteroquestionnaire to assess smoking cessation, tobacco use monitoring by healthcare professionals and individual factors associated with tobacco use during pregnancy. The primary outcome was the point prevalence of abstinence at delivery, which is the proportion of women reporting abstinence from smoking for at least 7 days at delivery. 4200 women who smoked tobacco during pregnancy will be recruited over the entire study period (33 months) to evaluate the effectiveness. An estimated 4585 participants will be included for all aims.
Ethics and dissemination: The study will be implemented in accordance with French regulations. The study including the consent process has been independently reviewed and approved by the French ethical board 'CPP Ile de France I' on 10 February 2022 (No CPPIDF1-2022-DI08-cat.2). The results will be disseminated on various academic and non-academic platforms. The results will be reported in international peer-reviewed journals and presented at international and national conferences.
期刊介绍:
BMJ Open is an online, open access journal, dedicated to publishing medical research from all disciplines and therapeutic areas. The journal publishes all research study types, from study protocols to phase I trials to meta-analyses, including small or specialist studies. Publishing procedures are built around fully open peer review and continuous publication, publishing research online as soon as the article is ready.